Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Recruiting · Phase 3 · NCT07007065
Conditions: Neovascular Age-related Macular Degeneration
At a glance
- Research payments reported, 2025
- $258,764
- U.S. investigators named
- 21
- Sites paid
- 20
- Planned or actual enrollment
- 561
About the trial
- Sponsor
- AbbVie
- Tested
- Surabgene Lomparvovec (ABBV-RGX-314) (drug), Ranibizumab Control (drug)
- Dates
- Started 2025-11-05; completion 2033-03
- Results posted
- Not yet
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis…
From ClinicalTrials.gov, last updated 2026-10-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $258,764 in research payments for this study in 2025 (105 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Suhail Alam, M.D. Retina Specialist · Phoenix, AZ
- Amr L. Dessouki, MD Ophthalmology · Campbell, CA
- Shahem Kawji, M.D. Ophthalmology · Newport Beach, CA
- Nikolas London, M.D. Ophthalmology · San Diego, CA
- Hani Salehi-had, M.D. Retina Specialist · Huntington Beach, CA
- Christian J. Sanfilippo, M.D. Retina Specialist · Encino, CA
- Murtaza K. Adam, MD Retina Specialist · Parker, CO
- Carl Noble, DO Retina Specialist · Longmont, CO
- Ryan M. Rich, MD Ophthalmology · Colorado Springs, CO
- Adam S. Berger, MD Ophthalmology · Winter Haven, FL
- Matthew A. Cunningham, MD Ophthalmology · Orlando, FL
- Pooja Garg, M.D. Ophthalmology · Coconut Creek, FL
- Shailesh K. Gupta, MD Retina Specialist · Deerfield Beach, FL
- Dennis M. Marcus, M.D. Ophthalmology · Augusta, GA
- Ramanath Bhandari, MD Ophthalmology · Springfield, IL
- Ivan R. Batlle, MD Ophthalmology · Lenexa, KS
- Jeremy D. Wolfe, MD Retina Specialist · Royal Oak, MI
- Sugat S. Patel, MD Retina Specialist · Dublin, OH
- David R. Almeida, MD, MBA, PHD Ophthalmology · Erie, PA
- Mona L. Camacci, MD Ophthalmology · Charleston, SC
- Eric Jablon, M.D. Ophthalmology · Charleston, SC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Springfield Clinic LLP $26,640
- Erie Retina Research LLC $23,799
- American Institute of Research $14,000
- The Retina PArtners $13,812
- $13,260
- Salehi Retina Institute Inc $13,062
- Eye Research Foundation Inc $13,062
- Retina Consultants San Diego Inc $12,500
- Midwest Retina Inc $12,500
- Charleston Neuroscience Ins LLC $12,240
- Eye Care Center of Northern $12,062
- Segal Drug Trials Inc $12,062
- Barnet Dulaney Perkins Eye Center $11,057
- Southeast Retina Center PC $11,057
- Vitreous and Retina Consultants $11,057
- Advanced Research LLC $11,057
- Associated Retinal Consultants PC $11,057
- Florida Retina Institute $6,120
- Colorado Retina Associates $6,120
- Retina Consultants of Southern $6,120
- Retina Associates LLC $6,120
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.